Alume Biosciences Overview

  • Year Founded
  • 2017

Year Founded

  • Status
  • Private

  • Employees
  • 11

Employees

  • Latest Deal Type
  • Later Stage VC

  • Latest Deal Amount
  • $2.16M

  • Investors
  • 9

Alume Biosciences General Information

Description

Developer of a nerve illumination technology designed to help doctors perform precision surgery. The company's technology illuminates nerves during surgery, making them visible to the surgical team, enabling surgeons to prevent nerve damage while performing complex organ surgeries.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 2223 Avenida de La Playa
  • Suite 205
  • La Jolla, CA 92037
  • United States
+1 (858)
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 2223 Avenida de La Playa
  • Suite 205
  • La Jolla, CA 92037
  • United States
+1 (858)

Alume Biosciences Timeline

2023202420252026
Financing Round

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Alume Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
11. Later Stage VC 01-May-2026 $2.16M Completed Clinical Trials - Phase 3
10. Later Stage VC (Series C) 18-Feb-2026 Completed Clinical Trials - Phase 3
9. Grant 08-Sep-2023 Completed Clinical Trials - Phase 3
8. Later Stage VC (Series B) 06-Jan-2023 Completed Clinical Trials - Phase 3
7. Grant 09-Sep-2022 Completed Pre-Clinical Trials
6. Grant 30-Sep-2020 Completed Pre-Clinical Trials
5. Early Stage VC (Series A2) 26-Aug-2020 Completed Pre-Clinical Trials
4. Early Stage VC (Series A) 11-Jul-2019 Completed Startup
3. Grant 15-Apr-2019 $1.18M Completed Startup
2. Accelerator/Incubator 15-Sep-2018 Completed Startup
To view Alume Biosciences’s complete valuation and funding history, request access »

Alume Biosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series C
Series B-1
Series B
Series A2
Series A1 400,000 $0.000010 $0.32 $4.02 $4.02 1x $4.02 2.1%
Series A 2,000,000 $0.000010 $0.32 $4.02 $4.02 1x $4.02 10.48%
To view Alume Biosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Alume Biosciences Patents

Alume Biosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4709405-A2 Fluorescein-labeled nerve targeting peptide formulations and related methods Pending 11-May-2023
US-20260306676-A1 Fluorescein-labeled nerve targeting peptide formulations and related methods Pending 11-May-2023
WO-2024233683-A2 Fluorescein-labeled nerve targeting peptide formulations and related methods Inactive 11-May-2023
WO-2024233683-A3 Fluorescein-labeled nerve targeting peptide formulations and related methods Inactive 11-May-2023
JP-2026516124-A Fluorescein-labeled neuronal targeting peptide formulation and related methods Pending 11-May-2023 A61K49/0041
To view Alume Biosciences’s complete patent history, request access »

Alume Biosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alume Biosciences Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds
U.S. Department of Health and Human Services Government
Small Business Innovation Research and Small Business Technology Transfer Programs Government
National Institutes of Neurological Disorders and Stroke Government
ALMA Life Sciences Venture Capital Minority
Biobrit Venture Capital Minority
You’re viewing 5 of 9 investors. Get the full list »

Alume Biosciences FAQs

  • When was Alume Biosciences founded?

    Alume Biosciences was founded in 2017.

  • Where is Alume Biosciences headquartered?

    Alume Biosciences is headquartered in La Jolla, CA.

  • What is the size of Alume Biosciences?

    Alume Biosciences has 11 total employees.

  • What industry is Alume Biosciences in?

    Alume Biosciences’s primary industry is Biotechnology.

  • Is Alume Biosciences a private or public company?

    Alume Biosciences is a Private company.

  • What is Alume Biosciences’s current revenue?

    The current revenue for Alume Biosciences is .

  • How much funding has Alume Biosciences raised over time?

    Alume Biosciences has raised $33.3M.

  • Who are Alume Biosciences’s investors?

    U.S. Department of Health and Human Services, Small Business Innovation Research and Small Business Technology Transfer Programs, National Institutes of Neurological Disorders and Stroke, ALMA Life Sciences, and Biobrit are 5 of 9 investors who have invested in Alume Biosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process